Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · IEX Real-Time Price · USD
2.790
+0.010 (0.36%)
Jul 2, 2024, 4:00 PM EDT - Market closed

Harvard Bioscience Revenue

Harvard Bioscience had revenue of $106.79M in the twelve months ending March 31, 2024, down -6.76% year-over-year. Revenue in the quarter ending March 31, 2024 was $24.51M, a -18.23% decrease year-over-year. In the year 2023, Harvard Bioscience had annual revenue of $112.25M, a decrease of -0.96%.

Revenue (ttm)
$106.79M
Revenue Growth
-6.76%
P/S Ratio
1.13
Revenue / Employee
$273,113
Employees
391
Market Cap
121.17M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023112.25M-1.09M-0.96%
Dec 31, 2022113.34M-5.57M-4.68%
Dec 31, 2021118.90M16.80M16.46%
Dec 31, 2020102.10M-14.08M-12.12%
Dec 31, 2019116.18M-4.60M-3.81%
Dec 31, 2018120.77M43.37M56.02%
Dec 31, 201777.41M-27.11M-25.94%
Dec 31, 2016104.52M-4.14M-3.81%
Dec 31, 2015108.66M1,000.000.00%
Dec 31, 2014108.66M3.49M3.32%
Dec 31, 2013105.17M-6.00M-5.40%
Dec 31, 2012111.17M2.31M2.12%
Dec 31, 2011108.86M685.00K0.63%
Dec 31, 2010108.18M22.41M26.12%
Dec 31, 200985.77M-2.28M-2.59%
Dec 31, 200888.05M4.64M5.57%
Dec 31, 200783.41M7.23M9.49%
Dec 31, 200676.18M8.75M12.98%
Dec 31, 200567.43M2.69M4.15%
Dec 31, 200464.75M12.72M24.45%
Dec 31, 200352.02M-5.36M-9.33%
Dec 31, 200257.38M16.51M40.40%
Dec 31, 200140.87M10.29M33.67%
Dec 31, 200030.57M4.40M16.80%
Dec 31, 199926.18M14.02M115.38%
Dec 31, 199812.15M689.87K6.02%
Dec 31, 199711.46M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Amylyx Pharmaceuticals 398.00M
Assertio Holdings 142.05M
Cellectis 12.13M
Omega Therapeutics 4.94M
I-Mab 3.90M
Revenue Rankings